Abstracts tagged "Health Assessment Questionnaire (HAQ)"

Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Evelyn Aranda Cano¹, Jessica Roldan Ortega², Yaneli Juárez-Vicuña³, Fausto Sánchez Muñoz⁴, Itzel Palafox Sosa⁵, Luz Angelica Viruel-Mejia⁶, David Vera Bustamante⁷, Luis H. Silveira Torre⁸, Angélica Vargas Guerrero⁹, Mayra Nadia Quintanar-Cuevas¹⁰, Erick Giovanny Bautista Jímenez¹¹ and Laura Aline Martinez-Martinez¹², ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, ⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁷Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁸Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁹Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ¹⁰Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ¹¹Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, ¹²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Vibeke Strand¹, Puja Khanna², Alan Kivitz³, Nana Kragh⁴, Aletta Falk⁵, Rehan Azeem⁶, Hugues Santin-Janin⁷ and Herbert Baraf⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Sobi, Stockholm, Sweden, ⁶Sobi Inc., Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
Abstract Number: 0495 • ACR Convergence 2024
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Manuel Ugarte-Gil², Risto Perich³, Cesar Pastor⁴, Graciela Alarcon⁵ and RV, Gamboa-Cardenas⁶, ¹Hncase, Arequipa, Peru, ²Universidad Cientifica del Sur, Lima, Lima, Peru, ³Hospital Almenara, Lima, Peru, ⁴UNMSM, LIMA, Peru, ⁵The University of Alabama at Birmingham, Oakland, CA, ⁶Universidad Científica del Sur, Lima, Lima, Peru
Background/Purpose: The triglyceride/glucose index (TGI) is a metabolic marker associated with insulin resistance and cardiovascular risk. In patients with Rheumatoid Arthritis (RA), chronic inflammation and…
Abstract Number: 0496 • ACR Convergence 2024
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Nils Steinz¹, Tjardo Maarseveen², Andrew Cope³, John Isaacs⁴, Aaron Winkler⁵, Thomas Huizinga⁶, Yann Abraham⁷ and Rachel Knevel¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ³King's College London, London, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵Pfizer Inc., Cambridge, MA, ⁶Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁷Janssen Research and Development, Beerse, Belgium
Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…
Abstract Number: 0510 • ACR Convergence 2024
Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis
Ahmad Alsaber¹, Adeeba Alherz², Huda Khraiss³, Ghaydaa Aldabie⁴, balqees alawadhi⁵, Jiazhu Pan⁶, Adel Alawadhi⁷, KHULOUD MOHAMMED⁸, Hoda Tarakmeh⁹, Aqeel Muhanna¹⁰, Yaser Ali¹¹ and mohammad Khudadah¹², and Kuwait Registry for Rheumatic Diseases (KRRD), ¹American University of Kuwait, Kuwait, Kuwait, ²Al-Amiri Hospital, Kuwait, Kuwait, ³Monash University, Melbourne, Queensland, Australia, ⁴ministry of health kuwait, kuwait, Kuwait, ⁵The Public Authority for Applied Education and Training (PAAET), Kuwait, Al Asimah, Kuwait, ⁶University of Strathclyde, Glasgow, Scotland, United Kingdom, ⁷Kuwait University, Kuwait, Kuwait, ⁸Farwaniya Hospital, Kuwait, Kuwait, ⁹MOH Kuwait, Kuwait, Kuwait, ¹⁰Ministry of Health, Kuwait, Al Farwaniyah, Kuwait, ¹¹Mubarek Al Kabeer Hospital, Kuwait city, Kuwait, ¹²ministery of health, kuwait, Kuwait
Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Andrew Sternlicht¹ and Meredith Todd², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 2015 • ACR Convergence 2024
Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
Austin Barry¹, Harlan Sayles¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Kaleb Michaud¹, Bridget Kramer¹, Jeff Newcomb¹, Mary Brophy³, Anne Davis-Karim⁴, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Veterans Affairs, Boston, MA, ⁴Veterans Affairs, Albuquerque, NM, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is associated with decreased health-related quality of life (HRQoL). The ACR endorses treat-to-target (TtT) urate-lowering therapy (ULT) for gout with a serum urate…
Abstract Number: 2214 • ACR Convergence 2024
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
Irtza Badar¹ and Martin Bergman², ¹Mercy Catholic Medical Center, Philadelphia, PA, ²self, Beach Haven, NJ
Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
Abstract Number: 2453 • ACR Convergence 2024
Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Elvira Lesmana¹, Ashley Keehn², Anukul Karn³, Andrea Pauly⁴, Margaret Breen-Lyles², Adam L Edwinson², Madhusudan Grover⁵ and Ashima Makol⁵, ¹Mayo Clinic, Rochester, MN, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, ³Mayo Clinic, Rochester, MN, Farmington Hills, MI, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
Abstract Number: 1981 • ACR Convergence 2023
The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up
Olga Sleglova¹, Jiri Baloun², Jindriska Gatterova¹, Xiao Svec¹, Olga Ruzickova¹, Karel Pavelka³ and Ladislav Senolt⁴, ¹Rheumatology Institute, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Hand osteoarthritis (HOA) is a heterogeneous disorder with two main subtypes, non-erosive and erosive. The progression of HOA is assessed by various radiographic scoring…
Abstract Number: 2229 • ACR Convergence 2023
Individual Entheseal Points Have Differential Frequency of Involvement and Impact on Patient Reported Outcomes in Patients with Active Psoriatic Arthritis: Pooled Analysis of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies
Laura Coates¹, Iain McInnes², Sibel Aydin³, Mitsumasa Kishimoto⁴, Philip J. Mease⁵, May Shawi⁶, Miriam Zimmermann⁷, Emmanouil Rampakakis⁸, Frederic Lavie⁹ and Dennis McGonagle¹⁰, ¹University of Oxford, Oxford, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Department of Medicine, Ottawa Hospital Riverside Campus, Ottawa, ON, Canada, ⁴Kyorin University School of Medicine, Yokohoma, Japan, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁶Immunology, Janssen Research & Development, LLC, Titusville, NJ, ⁷Immunology, Janssen Medical Affairs, LLC, Zug, Switzerland, ⁸McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, ¹⁰Leeds Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients with mono/oligoarticular psoriatic arthritis (PsA), swelling or tenderness of specific joints can be associated with poorer patient-reported outcomes (PROs) and physician global…
Abstract Number: 0229 • ACR Convergence 2023
Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout
HYUNSUE DO and Kiwon Moon, Kangwon National University Hospital, Seoul, South Korea
Background/Purpose: Gout, which is a prevalent form of inflammatory arthritis, is generally considered to be more effectively managed through medication. Besides of maintaining medication, they…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].